SiBone (NASDAQ:SIBN) SVP Sells $17,168.10 in Stock
by Sarita Garza · The Markets DailySiBone (NASDAQ:SIBN – Get Free Report) SVP Michael Pisetsky sold 1,335 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $12.86, for a total transaction of $17,168.10. Following the completion of the sale, the senior vice president directly owned 282,840 shares in the company, valued at approximately $3,637,322.40. This trade represents a 0.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
SiBone Price Performance
SIBN remained flat at $13.12 on Friday. 673,231 shares of the company traded hands, compared to its average volume of 599,931. The stock’s 50 day simple moving average is $14.69 and its 200 day simple moving average is $16.39. The stock has a market cap of $579.51 million, a price-to-earnings ratio of -29.82 and a beta of 0.77. SiBone has a 52 week low of $12.15 and a 52 week high of $21.89. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20.
SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. The business had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. Equities analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.
Institutional Investors Weigh In On SiBone
Large investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd purchased a new position in SiBone during the fourth quarter worth about $29,000. Royal Bank of Canada raised its holdings in shares of SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after acquiring an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of SiBone during the 3rd quarter valued at about $39,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of SiBone during the 4th quarter valued at about $53,000. Institutional investors own 98.11% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Needham & Company LLC lifted their target price on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. TD Cowen increased their price target on shares of SiBone from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Canaccord Genuity Group raised their price objective on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Truist Financial reaffirmed a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of SiBone in a research note on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.67.
View Our Latest Report on SIBN
About SiBone
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.